Online inquiry

IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14289MR)

This product GTTS-WQ14289MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CSF1R gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001288705.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1436
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ14289MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8272MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ4735MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ7022MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Fab C225
GTTS-WQ2763MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ5366MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ110MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 11F8
GTTS-WQ4674MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986089
GTTS-WQ15585MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW